Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.

Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Pharma industry: Year 2005 and beyond - Views on News from Equitymaster
  • E-MAIL
  • A  A  A
  • Feb 27, 2004

    Pharma industry: Year 2005 and beyond

    The year 2005 is likely to be a turning point for India Inc. in general, and the pharma industry in particular. This is in light of the fact that the new patent regime instituted by the WTO will come into force from January 1, 2005. Process patents, which are recognized in India and many other developing countries at present, will have to make way for product patents. Let us understand what would be the likely impact of this new patent regime on the Indian pharmaceutical industry.

    Before we analyse this aspect, let us first understand the differences between process patents and product patents. According to the process patent regime, a patented product can be made with a different process and can be sold in the market. Here, the process, and not the product, is patented. Considering the fact that chemistry allows one to synthesize a product in several ways, Indian companies, through their reverse engineering skills, have made replicas of various otherwise patented drugs & sold them in Indian markets. This cannot be done once product patents are recognized. This means that the companies, which were surviving on their reverse engineering skills, would die or have to look at other streams of revenues.

    The regime came into effect in developed nations in the year 1995, but the developing countries like India were given a grace period till the year 2005. The product patent has been instituted mainly in order to protect the intellectual property rights of companies that have initially developed the drug. The product patent regime will also help the original innovator to recover high costs of developing the drug. We must also understand that this new regime would significantly expand the market for original innovator companies. Earlier these companies shied away from developing markets due to the lack of adequate patent protection. Most developing countries had a process patent regime in place, and this has made the entry of original innovator companies unviable.

    Do Indian companies have what it takes to fight global majors?

    The answer lies in the market in which they are operating. Indian companies dominate the domestic market after government brought the 1970 Patents Act, in order to encourage the domestic industry. The share of Indian companies has increased from 20% in 1980 to 75% of the market in the year 2003. From net importer of pharma products, we became a net exporter. Pharma companies grew very fast and, as of today, there are as many as 20,000 licensed pharma companies in the country. But these figures might change after the introduction of new patent regime. The smaller companies may not survive. It is expected that the market share of patented drugs after 2005 will be 15% of the total pharma industry in the country.

    Considering the fact that most of the patented drugs in the country would be brought here by the multinationals, the market share of the companies and most importantly profitability will increase. While Indian companies would continue to sell the drugs that have been patented pre-1995, MNC's, with their new and patented drugs, may capture a larger share of the market going forward, and that too among different therapeutic segments. However, pricing of drugs post the patent regime may be a key factor to the growth of MNC pharma companies in the country.

    For Indian companies, there would arise a need to find areas where they have a sizeable opportunity to grow apart from the domestic market. Reverse engineered pharma products have their own life and may not be enough to sustain Indian companies over the long-term. Indian companies recognizing this challenge are exploring various options, for example the area of new chemical entities (in simple terms, a new drug altogether). Though Indian companies are gearing themselves for this challenge it will take a while for them to make any impact in the patented drugs field. Companies like Ranbaxy Laboratories, Dr. Reddy's Labs, Wockhardt, Cipla, and Nicholas Piramal have invested money in research. However, the returns on these investments will take some time to be realized. These companies have started the primary research in synthesizing new chemical entities (NCE), but clinical trials are still the largest roadblock for India as it is a time consuming, cumbersome and a costly exercise. However, over the long-term, this option is likely to yield the best results for Indian pharma companies.

    The other option available for Indian companies is contract research. With strong analytical skills that Indians possess and their proven chemistry capabilities, contract research can be a viable option for Indian companies. Also these companies, which have good bulk manufacturing facilities, can benefit by manufacturing the same drug once it comes out of clinical trials into the market as it would be easy for them to get a contract for bulk orders since they will be associated with the project since inception.

    Marketing is another critical factor that is likely to play a big role in the success of pharma companies. While bulk drugs represent a huge opportunity, the aim of leading Indian companies is to move up the value chain towards finished dosage forms and into formulations where margins are better and companies like Ranbaxy and Dr Reddy's have already taken a lead in this field. They, over the last several years, have painstakingly built their own marketing infrastructure in the US. Ranbaxy has created a good brand name amongst in the prescription drugs market in US. Apart from this, both these companies are highest spenders in R&D in the country and are also big players in the domestic formulations markets.

    Thus, with the new patent regime impending, the focus on the exports market can save Indian companies from any unlikely event post 2005. But as cited earlier, R&D and building their own presence through strong marketing network is critical to the success in pharma industry after the year 2005.



    Equitymaster requests your view! Post a comment on "Pharma industry: Year 2005 and beyond". Click here!


    More Views on News

    Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

    Aug 14, 2017

    A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

    Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

    Aug 14, 2017

    GST impact coupled with price erosion in US leads to lower profits for the quarter.

    Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

    Aug 8, 2017

    Profits plunge due to higher raw material costs.

    The Power of 5 Minutes (The 5 Minute Wrapup)

    Jun 16, 2017

    Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

    Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

    Jun 23, 2017

    Net Profit lower due to exceptional items in the previous year.

    More Views on News

    Most Popular

    This Small Cap Can Drive Chinese Players Out of India (and Make a Fortune in the Process)(The 5 Minute Wrapup)

    Aug 17, 2017

    A small-cap Indian company with high-return potential and blue-chip-like stability is set to supplant the Chinese players in this niche segment.

    The Most Important Innovation in Finance Since Gold Coins(Vivek Kaul's Diary)

    Aug 10, 2017

    Bill connects the dots...between money and growth, real money and real resources, gold and cryptocurrencies...and between gold, cryptocurrencies, and time.

    It's the Best Time to Buy IT Stocks(Daily Profit Hunter)

    Aug 16, 2017

    The IT Sector could be in an uptrend till February 2019. Are you prepared to ride the trend?

    Bitcoin Continues Stellar Rise(Chart Of The Day)

    Aug 10, 2017

    Bitcoin hits an all-time high, is there more upside left?

    5 Steps To Become Financially Independent(Outside View)

    Aug 16, 2017

    Ensure your financial Independence, and pledge to start the journey towards financial freedom today!

    Copyright © Equitymaster Agora Research Private Limited. All rights reserved.
    Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

    LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.

    SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

    Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
    Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407

    Become A Smarter Investor In
    Just 5 Minutes

    Multibagger Stocks Guide 2017
    Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
    We will never sell or rent your email id.
    Please read our Terms


    Aug 23, 2017 03:25 PM